When I read headlines about brain-computer interfaces—and there’s a new one roughly every 72 hours, each seemingly announcing that the future has arrived—I’m reading them with the same part of my brain that reads MRI reports and discharge summaries. I’m looking for the mechanism, the sample size, the follow-up period, and the part of the press release that got quietly omitted. And what I keep finding is a field where the actual science is genuinely remarkable, the engineering is legitimately impressive, and the gap between what’s been demonstrated and what’s being promised is roughly the width of the Grand Canyon.
So here’s where brain-computer interfaces actually stand in March 2026. Not the press release version. Not the “we’re five years from The Matrix” version. The clinical reality, company by company, with the caveats attached.
What a BCI actually does (the 30-second version)
Your motor cortex generates electrical signals when you intend to move. In a healthy nervous system, those signals travel down your spinal cord, through peripheral nerves, and to your muscles. In someone with a spinal cord injury or ALS, the signals still fire at the top—the brain is still doing its job—but the wiring downstream is broken. A brain-computer interface picks up those electrical signals directly from the cortex and routes them to an external device instead of to muscles. You think about moving your hand, the electrodes record the neural activity, a decoder translates it into a digital command, and a cursor moves on a screen or a robotic arm reaches for a cup. That’s it. That’s the core mechanism. Everything else is engineering.
The engineering, of course, is where it gets complicated—and where the companies diverge in ways that matter enormously for which patients actually benefit, when, and at what risk.
Neuralink: The one you’ve heard of
Neuralink gets roughly 95% of the media coverage in this space despite being neither the first nor the furthest along clinically. What they have is Elon Musk, which in the attention economy is worth more than a decade of peer-reviewed publications. The N1 implant is a coin-sized device with 1,024 electrodes distributed across 64 ultra-thin polymer threads, inserted into the motor cortex by a custom surgical robot. The threads are thinner than a human hair—about 5 microns—and that’s genuinely impressive from a materials science standpoint. The pitch is high electrode count plus wireless transmission plus a cosmetically invisible implant that sits flush with the skull.
As of early 2026, Neuralink has 21 participants enrolled in its global clinical trials, up from 12 in September 2025. The first patient, Noland Arbaugh—quadriplegic from a diving accident—demonstrated the ability to control a cursor, play video games, browse the internet, and post on social media using the implant. The third patient, Brad Smith, who has ALS and is ventilator-dependent, can type using the device. These are real outcomes. They matter. A person who cannot move anything below the neck using thought alone to navigate a computer is not a small thing.
But—and this is where my press release detector starts going off—Musk announced on December 31, 2025, that Neuralink would begin “high-volume production” of BCI devices and move to “almost entirely automated surgical procedures” in 2026. He also announced the Blindsight implant for restoring vision in the blind would begin its first patient trial this year. If you’ve followed Musk’s timeline promises across any of his companies—Tesla Full Self-Driving, the Cybertruck, the Boring Company’s Vegas Loop—you know that announced timelines and delivered timelines have a relationship best described as aspirational. “High-volume production” in 2026 from a company with 21 trial participants is a claim that requires a lot of intermediate steps that haven’t been publicly demonstrated: manufacturing consistency, surgical standardization, long-term safety data, and FDA clearance for anything beyond an investigational device. None of those things have happened yet.
The first patient also had a documented issue: some electrode threads retracted from the cortex after implantation, reducing the number of functional electrodes. Neuralink adjusted its approach for subsequent patients, but this is exactly the kind of biocompatibility challenge that doesn’t show up in the demo reel. Brain tissue is not a circuit board. It’s alive, it moves, it forms scar tissue around foreign objects, and it does not appreciate being punctured by 64 threads, no matter how thin they are.
Synchron: The one that doesn’t require brain surgery
Synchron is doing something fundamentally different, and I think the approach deserves more attention than it gets. Their Stentrode device is an endovascular BCI—it’s threaded up through the jugular vein and deployed inside a blood vessel on the surface of the motor cortex, using the same catheter techniques that interventional neurologists (my people) use every day to treat strokes and aneurysms. No craniotomy. No opening the skull. No penetrating brain tissue. The median procedure time in their COMMAND trial was 20 minutes.
The tradeoff is resolution. The Stentrode has 16 electrodes compared to Neuralink’s 1,024. It’s sitting inside a blood vessel, not directly in cortical tissue, so the signals it picks up are less granular—think of it as the difference between sitting in the front row at a concert versus listening from the parking lot. You can still hear the music, but you’re not picking up the individual instruments. For the current application—point-and-click cursor control, typing, navigating apps—that’s sufficient. An ALS patient in their trial became the first person to control an iPad with a BCI, using Apple’s native Switch Control accessibility feature. He later connected to an Apple Vision Pro and Amazon Alexa using only his thoughts. These are consumer devices, unmodified, working with a brain implant through standard accessibility protocols. That’s a very different value proposition than a research demo in a lab.
Synchron’s COMMAND trial—six patients, 12-month follow-up—met its primary safety endpoint with no device-related serious adverse events to the brain or vasculature. They raised $200 million in Series D funding in late 2025, backed by Bezos, Gates, and the Qatar Investment Authority, and are preparing pivotal trials for 2026 ahead of commercial approval. They’ve also announced a next-generation whole-brain interface with significantly higher channel counts, though details won’t arrive until later this year.
The strategic bet Synchron is making is that a lower-resolution device implanted through an existing, well-understood medical procedure will reach more patients faster than a higher-resolution device that requires brain surgery. From a regulatory and clinical adoption standpoint, that bet has a lot of logic behind it. Interventional neuroradiologists already know how to navigate catheters through cerebral vasculature. The training curve is short. The risk profile maps onto procedures we’ve been doing for decades.
BrainGate and Blackrock Neurotech: The ones that were here first
The BrainGate consortium—a collaboration across Mass General Brigham, Brown University, Stanford, and several other institutions—has been running clinical trials of implantable BCIs since 2004, which is two decades before Neuralink implanted its first patient. Their technology is built on Blackrock Neurotech’s Utah Array, a grid of 96 silicon microelectrodes that penetrates the cortex. It’s the workhorse of the field. Nathan Copeland, implanted in 2015, holds the record for longest continuous use of a brain-computer interface. In 2016, he used a robotic arm to fist-bump Barack Obama, which remains the single best piece of BCI marketing ever produced despite not being marketing at all.
In 2025, a BrainGate team at UC Davis demonstrated that a man with ALS could speak through a BCI-driven voice synthesizer reconstructed from recordings of his pre-disease voice. More recently, a BrainGate study published in Nature Neuroscience showed two paralyzed patients typing on a standard QWERTY keyboard layout using attempted finger movements—not imagined cursor control, actual attempted typing—at speeds approaching 90 characters per minute. That’s not far from the average typing speed of a non-disabled person on a phone. The decoder is getting better because the algorithms are getting better, and the algorithms are getting better because we have more data from more patients over longer periods. This is the boring, incremental, deeply important work that doesn’t generate Musk-level headlines but is actually what moves the field forward.
Precision Neuroscience: The one designed to come back out
Founded by Neuralink co-founder Benjamin Rapoport, Precision takes yet another approach. Their Layer 7 Cortical Interface is an ultra-thin film—one-fifth the thickness of an eyelash—studded with 1,024 platinum microelectrodes. It sits on the brain surface without penetrating tissue, slipped through a small slit in the skull. The critical difference: it’s designed to be safely removable. Every other invasive BCI is essentially permanent. Precision’s device can come out without damaging the cortex, which is a significant advantage for a field where the long-term effects of brain implants are still being studied.
Precision received FDA 510(k) clearance—the first full regulatory clearance for any of the new commercial BCI technologies—for implants lasting up to 30 days, and they’ve performed 38 human implant procedures. Their current application is short-term brain mapping and neural data collection, not yet chronic implantation for daily use. But the data they’re collecting is building the training sets for neural decoding algorithms that could eventually power long-term devices.
What’s actually hard (the part nobody puts on the slide deck)
Here’s what I think about when I read BCI press releases, and what I wish the coverage spent more time on:
Signal degradation over time. The brain forms glial scar tissue around penetrating electrodes. The signal quality starts high and degrades over months to years as the immune response walls off the foreign object. This is the single biggest unsolved problem in chronic invasive BCIs, and no company has publicly demonstrated a solution that works at scale over five-plus years.
The decoder problem. Current BCIs require calibration—sometimes daily—because the neural signals drift. The relationship between a specific pattern of neural activity and an intended movement isn’t fixed. It shifts as neurons adapt to the implant, as the user’s neural strategies change, and as electrodes move or degrade. Making decoders that stay accurate without constant recalibration is an active area of research, and AI is helping, but it’s not solved.
Surgical risk. Any procedure involving the brain carries risk. Infection, hemorrhage, device failure requiring revision surgery—these are not theoretical concerns. They’re the everyday calculus of neurosurgery. Neuralink’s thread retraction in their first patient is a concrete example. Synchron’s endovascular approach has a lower risk profile precisely because it doesn’t penetrate the brain, but even catheter-based procedures have complication rates.
The regulatory path. These devices are in early feasibility trials. The road from there to FDA-approved commercial products typically takes years—pivotal trials with larger patient populations, long-term follow-up data, manufacturing quality controls, post-market surveillance plans. Musk saying “high-volume production in 2026” doesn’t change the regulatory timeline. The FDA moves at the speed of evidence, not the speed of X posts.
Where this goes
The honest assessment: BCIs for people with severe paralysis will almost certainly become commercially available within the next three to five years. Not as consumer products—as medical devices, implanted by neurosurgeons, prescribed for specific clinical indications, and covered (eventually) by insurance. The first approved products will probably do what the current trials are demonstrating: cursor control, typing, basic device navigation. Not telepathy. Not memory enhancement. Not uploading your consciousness to the cloud.
The longer-term applications—speech decoding for people who’ve lost the ability to talk, sensory feedback for prosthetic limbs, treatment of neuropsychiatric conditions—are genuinely possible but further out. They require higher-resolution interfaces, better algorithms, and a much deeper understanding of neural coding than we currently have.
What I want people to take away from this is that the technology is real, the progress is meaningful, and the patients benefiting from these devices are experiencing something that would have been science fiction 20 years ago. But the field is in its early clinical phase, and the distance between “a paralyzed person can move a cursor” and “BCIs are a consumer product” is enormous—measured not in engineering breakthroughs but in safety data, regulatory milestones, and the slow, grinding, essential work of proving that these devices help more than they harm over the long term.
We cover the full history, science, and engineering of brain-computer interfaces—from the earliest EEG experiments to every company and approach described above—across 48 lectures in our Neuroprosthetics & Brain-Computer Interfaces course. If this piece made you want the granular version, that’s where it lives.